Strides Pharma Science Limited considered and approved offering for subscription, on a private placement basis, up to 1,500 senior, secured, rated, unlisted, redeemable, Non-Convertible Debentures (NCDs) of face value INR 10,00,000 each aggregating up to INR 1500 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
859 INR | -0.21% | +1.17% | +32.30% |
May. 23 | Strides Pharma Science Turns to Consolidated Net Profit in Fiscal Q4; Shares Down 3% | MT |
May. 22 | Transcript : Strides Pharma Science Limited, Q4 2024 Earnings Call, May 22, 2024 |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+32.30% | 948M | |
+15.37% | 41.97B | |
+22.56% | 22.34B | |
+15.19% | 15.25B | |
+16.53% | 14B | |
+49.78% | 12.06B | |
-10.77% | 6.8B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+14.18% | 5.49B |
- Stock Market
- Equities
- STAR Stock
- News Strides Pharma Science Limited
- Strides Pharma Science Limited Approves Offering for Subscription Up to 1,500 Senior, Secured, Rated, Unlisted, Redeemable, Non-Convertible Debentures